Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | How will telisotuzumab adizutecan benefit patients with colorectal cancer?

Michael Cecchini, MD, Yale University, New Haven, CT, examines the potential of telisotuzumab adizutecan, an antibody-drug conjugate targeting c-Met, in colorectal cancer, highlighting that c-Met is universally expressed in colorectal cancer tumor cells, making it a valid target for treatment. Data from a Phase I trial (NCT05029882), which was unselected for C-Met expression, showed improvements in overall survival and progression-free survival, demonstrating the high activity of these agents beyond standard of care. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Well, T-Met-A is an antibody drug conjugate against C-Met. So the results from last year and even before that at ASCO, the monotherapy data, I think, established C-Met as a valid target in this disease. Now, I think it’s important to note that C-Met is expressed in virtually all of colorectal cancer. There’s different degrees of expression, but some degree of C-Met expression is expressed universally in colorectal cancer tumor cells...

Well, T-Met-A is an antibody drug conjugate against C-Met. So the results from last year and even before that at ASCO, the monotherapy data, I think, established C-Met as a valid target in this disease. Now, I think it’s important to note that C-Met is expressed in virtually all of colorectal cancer. There’s different degrees of expression, but some degree of C-Met expression is expressed universally in colorectal cancer tumor cells. So these agents are potentially going to play a role in virtually all patients with colorectal cancer. So the data I presented today was unselected for C-Met expression. So patients weren’t preselected for high levels of C-Met expression. And in that unselected patient population, we revealed the improvements in overall survival, although that was not statistically significant, probably due to the sample size, as well as the progression-free survival, which did have a hazard ratio that did not cross one confidence interval. So I think when you look at the monotherapy data, the combination data, we see that these antibody drug conjugates and C-Met have high activity beyond what we see with the standard of care and put C-Met on the map as a relevant target.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.